Hendra virus: A one health tale of flying foxes, horses and humans

Future Microbiology

Volumn 8, Issue 4, 2013, Pages 461-474

  Hazelton, Briony ^a   Ba Alawi, Fatma ^a   Kok, Jen ^a,b   Dwyer, Dominic E ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

flying foxes; Hendra virus; Henipavirus; horses; Paramyxoviridae

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; RIBAVIRIN; SUBUNIT VACCINE; VACCINE; VIRUS RNA;

ANTIVIRAL THERAPY; AUSTRALIA; BIOSAFETY; CEREBROSPINAL FLUID; CLINICAL FEATURE; DISEASE CARRIER; ELECTRON MICROSCOPY; ENCEPHALITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; GEOGRAPHIC DISTRIBUTION; HENDRA VIRUS INFECTION; HISTOPATHOLOGY; HORSE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION RISK; LOOP MEDIATED ISOTHERMAL AMPLIFICATION; MOLECULAR DIAGNOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTIVE EQUIPMENT; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY DISTRESS; REVIEW; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; SEROLOGY; SERUM; TACHYPNEA; VIRAL TROPISM; VIRION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; CHIROPTERA; HENDRA VIRUS; HENIPAVIRUS INFECTIONS; HORSE DISEASES; HORSES; HUMANS; ZOONOSES;

ANIMALIA; EQUIDAE; HENDRA VIRUS; HENIPAVIRUS; PARAMYXOVIRIDAE; PTEROPODIDAE;

EID: 84875748310     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.19     Document Type: Review

References (84)

1. Selvey LA, Wells RM, McCormack JG et al. Infection of humans and horses by a newly described morbillivirus. Med. J. Aust. 162(12), 642-645 (1995).
2. Tulsiani SM, Graham GC, Moore PR et al. Emerging tropical diseases in Australia. Part 5. Hendra virus. Ann. Trop. Med. Parasitol. 105(1), 1-11 (2011).
3. Murray K, Selleck P, Hooper P et al. A morbillivirus that caused fatal disease in horses and humans. Science 268, 94-97 (1995).
4. Wang L-F, Yu M, Hansson E et al. The exceptionally large genome of Hendra virus: support for creation of a new genus within the family Paramyxoviridae. J. Virol. 74(21), 9972-9979 (2000).
5. Marsh GA, de Jong C, Barr JA et al. Cedar virus: a novel henipavirus isolated from Australian bats. PLoS Pathog. 8, e1002836 (2012).
6. Breed AC, Breed MF, Meers J, Field HE. Evidence of endemic Hendra virus infection in flying-foxes (Pteropus conspicillatus) - implications for disease risk management. PLoS ONE 6(12), e28816 (2011).
7. Mahalingam S, Herrero LJ, Playford EG et al. Hendra virus: an emerging paramyxovirus in Australia. Lancet Infect. Dis. 12(10), 799-807 (2012).
8. Plowright RK, Foley P, Field HE et al. Urban habituation, ecological connectivity and epidemic dampening: the emergence of Hendra virus from flying foxes (Pteropus spp.). Proc. R. Soc. B 278(1725), 3703-3712 (2011).
9. Field H, de Jong C, Melville D et al. Hendra virus infection dynamics in Australian fruit bats. PLoS ONE 6, e28678 (2011).
10. Halpin K, Hyatt AD, Fogarty R et al. Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am. J. Trop. Med. Hyg. 85(5), 946-951 (2011).
11. Field H, Young P, Yob JM, Mills J, Hall L, Mackenzie J. The natural history of Hendra and Nipah viruses. Microbes Infect. 3(4), 307-314 (2001).
12. Hess IMR, Massey PD, Walker B, Middleton DJ, Wright TM. Hendra virus: what do we know? NSW Public Health Bull. 22(5-6), 118-122 (2011).
13. Marsh GA, Haining J, Hancock TJ et al. Experimental infection of horses with Hendra virus/Australia/horse/2008/Redlands. Emerg. Infect. Dis. 17(12), 2232-2238 (2011).
14. Fogarty R, Halpin K, Hyatt AD, Daszak P, Mungall BA. Henipavirus susceptibility to environmental variables. Virus Res. 132(1-2), 140-144 (2008).
15. Playford EG, McCall B, Smith G et al. Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg. Infect. Dis. 16, 219-223 (2010).
16. Selvey L, Taylor R, Arklay A, Gerrard J. Screening of bat carers for antibodies to equine morbillivirus. Commun. Dis. Intell. 20(22), 477-478 (1996).
17. Dups J, Middleton D, Yamada M et al. A new model for Hendra virus encephalitis in the mouse. PLoS ONE 7(7), e40308 (2012).
18. Weingartl HM, Berhane Y, Czub M. Animal models of henipavirus infection: a review. Vet. J. 181(3), 211-220 (2009).
19. Li M, Embury-Hyatt C, Weingartl HM. Experimental inoculation study indicates swine as a potential host for Hendra virus. Vet. Res. 41(3), 33 (2010).
20. Hyatt AD, Zaki SR, Goldsmith CS, Wise TG, Hengstberger SG. Ultrastructure of Hendra virus and Nipah virus within cultured cells and host animals. Microbes Infect. 3(4), 297-306 (2001).
21. Rollin PE, Rota PA, Zaki S, Ksiazek TG. Hendra and Nipah viruses. In: Manual of Clinical Microbiology (10th Edition). Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (Eds). ASM Press, Washington, DC, USA, 1479-1487 (2011).
22. Wang L, Harcourt BH, Yu M et al. Molecular biology of Hendra and Nipah viruses. Microbes Infect. 3(4), 279-287 (2001).
23. Halpin K, Young PL, Field HE, Mackenzie JS. Isolation of Hendra virus from pteropid bats: a natural reservoir of Hendra virus. J. Gen. Virol. 81(Pt 8), 1927-1932 (2000).
24. Eaton BT, Broder CC, Middleton D, Wang L-F. Hendra and Nipah viruses: different and dangerous. Nat. Rev. Microbiol. 4(1), 23-35 (2006).
25. Bossart KN, Wang L-F, Eaton BT, Broder CC. Functional expression and membrane fusion tropism of the envelope glycoproteins of Hendra virus. Virology 290(1), 121-135 (2001).
26. Park MS, Shaw ML, Munoz-Jordan J et al. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J. Virol. 77(2), 1501-1511 (2003).
27. Rodriguez JJ, Parisien JP, Horvath CM. Nipah virus V protein evades alpha and gamma interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J. Virol. 76(22), 11467-11483 (2002).
28. Bishop KA, Stantchev TS, Hickey AC et al. Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J. Virol. 81(11), 5893-5901 (2007).
29. Bossart KN, Broder CC. Developments toward effective treatments for Nipah and Hendra virus infection. Expert Rev. Anti Infect. Ther. 4(1), 43-55 (2006).
30. Bowden TA, Crispin M, Harvey DJ, Jones EY, Stuart DI. Dimeric architecture of the Hendra virus attachment glycoprotein: evidence for a conserved mode of assembly. J. Virol. 84(12), 6208-6217 (2010).
31. Pernet O, Wang YE, Lee B. Henipavirus receptor usage and tropism. Curr. Top. Microbiol. Immunol. 359, 59-78 (2012).
32. Mackenzie JS, Field HE. Emerging encephalitogenic viruses: lyssaviruses and henipaviruses transmitted by frugivorous bats. Arch. Virol. Suppl. 18, 97-111 (2004).
33. Wong KT, Tan CT. Clinical and pathological manifestations of human henipavirus infection. Curr. Top. Microbiol. Immunol. 359, 95-104 (2012).
34. Wong KT, Robertson T, Ong BB et al. Human Hendra virus infection causes acute and relapsing encephalitis. Neuropathol. Appl. Neurobiol. 35(3), 296-305 (2009).
35. Field H, Schaaf K, Kung N et al. Hendra virus infection with novel clinical features, Australia. Emerg. Infect. Dis. 16(2), 338-340 (2010).
36. Hanna JN, McBride WJ, Brookes DL et al. Hendra virus infection in a veterinarian. Med. J. Aust. 185(10), 562-564 (2006).
37. Taylor C, Playford EG, McBride WJH, McMahon J, Warrilow D. No evidence of prolonged Hendra virus shedding by 2 patients, Australia. Emerg. Infect. Dis. 18(12), 2025-2027 (2012).
38. O'Sullivan JD, Allworth AM, Paterson DL et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet 349(9045), 93-95 (1997).
39. Daniels P, Ksiazek T, Eaton BT. Laboratory diagnosis of Nipah and Hendra virus infections. Microbes Infect. 3(4), 289-295 (2001).
40. Smith IL, Haplin K, Warrilow D, Smith GA. Development of a fluorogenic RT-PCR assay (TaqMan) for the detection of Hendra virus. J. Virol. Methods 98(1), 33-40 (2001).
41. Feldman KS, Foord A, Heine HG et al. Design and evaluation of consensus PCR assays for henipaviruses. J. Virol. Methods 161(1), 52-57 (2009).
42. Foord AJ, Middleton D, Heine HG. Hendra virus detection using loop-mediated isothermal amplification. J. Virol. Methods 181(1), 93-96 (2012).
43. Smith I, Broos A, de Jong C et al. Identifying Hendra virus diversity in pteropid bats. PLoS ONE 6(9), e25275 (2011).
44. Wang L-F, Daniels P. Diagnosis of henipavirus infection: current capabilities and future directions. Curr. Top. Microbiol. Immunol. 359, 179-196 (2012).
45. Dukes JP, King DP, Alexandersen S. Novel reverse transcription loop-mediated isothermal amplification for rapid detection of foot-and-mouth disease virus. Arch. Virol. 151(6), 1093-1106 (2006).
46. Kaku Y, Noguchi A, Marsh GA et al. Antigen capture ELISA system for henipaviruses using polyclonal antibodies obtained by DNA immunization. Arch. Virol. 157(8), 1605-1609 (2012).
47. Chiang CF, Lo MK, Rota PA, Spiropoulou CF, Rollin PE. Use of monoclonal antibodies against Hendra and Nipah viruses in antigen capture ELISA. Virol. J. 7, 115 (2010).
48. Crameri G, Wang L-F, Morrissy C, White J, Eaton BT. A rapid immune plaque assay for the detection of Hendra and Nipah viruses and anti-virus antibodies. J. Virol. Methods 99(1-2), 41-51 (2002).
49. Kaku Y, Noguchi A, Marsh GA et al. A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein. J. Virol. Methods 160(1-2), 7-13 (2009).
50. Barclay AJ, Paton DJ. Hendra (equine morbillivirus). Vet. J. 160(3), 169-176 (2000).
51. Rockx B, Bossart KN, Feldmann F et al. A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment. J. Virol. 84(19), 9831-9839 (2010).
52. Broder CC. Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr. Opin. Virol. 2(2), 176-187 (2012).
53. Chong H-T, Kamarulzaman A, Tan C-T et al. Treatment of acute Nipah encephalitis with ribavirin. Ann. Neurol. 49(6), 810-813 (2001).
54. Wright PJ, Crameri G, Eaton BT. RNA synthesis during infection by Hendra virus: an examination by quantitative real-time PCR or RNA accumulation, the effect of ribavirin and the attenuation of transcription. Arch. Virol. 150(3), 521-532 (2005).
55. Porotto M, Orefice G, Yokoyama CC et al. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J. Virol. 83(10), 5148-5155 (2009).
56. Freiberg AN, Worthy MN, Lee B, Holbrook MR. Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection. J. Gen. Virol. 91(Pt 3), 765-772 (2010).
57. Pallister J, Middleton D, Crameri G et al. Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. J. Virol. 83(22), 11979-11982 (2009).
58. Georges-Courbot MC, Contamin H, Faure C et al. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob. Agents Chemother. 50(5), 1768-1772 (2006).
59. Bossart KN, Broder CC. Developments toward effective treatments for Nipah and Hendra virus infection. Expert Rev. Anti Infect. Ther. 4(1), 43-55 (2006).
60. Porotto M, Doctor L, Carta P et al. Inhibition of Hendra virus fusion. J. Virol. 80(19), 9837-9849 (2006).
61. Porotto M, Rockx B, Yokoyama CC et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of Paramyxovirus fusion activation during viral entry. PLoS Pathog. 6(10), e1001168 (2010).
62. Zhu Z, Bossart KN, Bishop KA et al. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J. Infect. Dis. 197(6), 846-853 (2008).
63. Bossart KN, Zhu Z, Middleton D et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. PLoS Pathog. 5(10), e1000642 (2009).
64. Bossart KN, Geisbert TW, Feldmann H et al. A neutralizing human monoclonal antibody protects African green monkeys from Hendra virus challenge. Sci. Transl. Med. 3(105), 105ra103 (2011).
65. Plowright RK, Field HE, Smith C et al. Reproduction and nutritional stress are risk factors for Hendra virus infection in little red flying foxes (Pteropus scapulatus). Proc. Biol. Sci. 275(1636), 861-869 (2008).
66. Pallister J, Middleton D, Wang L-F et al. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine 29(34), 5623-5630 (2011).
67. Mungall BA, Middleton D, Crameri G et al. Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J. Virol. 80(24), 12293-12302 (2006).
68. McEachern JA, Bingham J, Crameri G et al. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine 26(31), 3842-3852 (2008).
69. Tan CT, Goh KJ, Wong KT et al. Relapsed and late-onset Nipah encephalitis. Ann. Neurol. 51(6), 703-708 (2002).
70. Mendez DH, Judd J, Speare R. Unexpected result of Hendra virus outbreaks for veterinarians, Queensland, Australia. Emerg. Infect. Dis. 18(1), 83-85 (2012).
71. Queensland Government: Department of Agriculture, Fisheries and Forestry. What is Hendra virus? www.daff.qld.gov.au/4790-15093.htm (Accessed 16 November 2012)
72. Queensland Government: Department of Agriculture, Fisheries and Forestry. News release, 26 July 2011: Hendra virus infection confirmed in a dog. www.daff.qld.gov.au/30-20717.htm (Accessed 23 November 2012)
73. Queensland Government: Department of Agriculture, Fisheries and Forestry. Signs of Hendra virus in horses. www.daff.qld.gov.au/4790-20805.htm (Accessed 23 November 2012)
74. Animal Health Australia. Response policy briefs (Version 3.3).Australian Veterinary Emergency Plan (AUSVETPLAN), Edition 3, Primary Industries Ministerial Council, Canberra, ACT (2009).www.animalhealthaustralia.com.au/wp- content/uploads/2011/04/RPB3-2- 02FINAL27Mar09.pdf (Accessed 11 December 2012)
75. Biosecurity Queensland. Guidelines for veterinarians handling potential Hendra virus infection in horses (Version 4.2).State of Queensland, Department of Employment, Economic Development and Innovation (2011).www.daff.qld.gov.au/ documents/Biosecurity- GeneralAnimalHealthPestsAndDiseases/ Hendra- GuidelinesForVets.pdf (Accessed 23 November 2012)
76. ISO 15190:2003 - Medical laboratories - requirements for safety (2004).www.ifcc.org/ifccfiles/docs/150412200405.pdf (Accessed 20 September 2012)
77. Communicable Diseases Network Australia. Hendra virus national guidelines for public health units. www.commcarelink.health.gov.au/internet/ main/publishing.nsf/Content/cdna-song-hendra.htm (Accessed 20 September 2012)
78. National Pathology Accreditation and Advisory Council (NPAAC). Requirements for the packaging and transport of pathology specimens and associated materials (2007).
79. www.health.gov.au/internet/main/publishing. nsf/Content/health-npaac- publication.htm (Accessed 21 September 2012)
80. Young J. Queensland Health statement re: monoclonal antibodies. www.health.qld.gov.au/news/media-releases/ monoclonal0531.pdf (Accessed 12 December 2012)
81. University of Queensland: Australian Institute of Bioengineering and Nanotechnology. Hendra virus facts. www.aibn.uq.edu.au/hendra-virus-facts (Accessed 5 February 2013)
82. Queensland Government: Department of Agriculture, Fisheries and Forestry. Reducing the risk of horses becoming infected with Hendra virus. www.daff.qld.gov.au/4790-20806.htm (Accessed 11 December 2012)
83. Queensland Government: Department of Agriculture, Fisheries and Forestry. Reducing the risk of people becoming infected with Hendra virus. www.daff.qld.gov.au/4790-20807.htm (Accessed 11 December 2012)
84. New South Wales Government: Department of Primary Industries. Hendra virus vaccine information for vets. www.dpi.nsw.gov.au/agriculture/livestock/ horses/health/general/hendra-virus/vaccine-info-vets (Accessed 4 February 2013)